The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross‐national comparison study

医学 中国 药品审批 肿瘤科 环境卫生 药理学 政治学 药品 法学
作者
Jian Yan,Hongtao Li,Pei Zhang,Man Yu,Huan Zhang,Xin Li
出处
期刊:International Journal of Cancer [Wiley]
卷期号:152 (11): 2351-2361 被引量:4
标识
DOI:10.1002/ijc.34427
摘要

Immune checkpoint inhibitors (ICIs) are currently one of the most popular treatment methods for cancers. Several ICIs have been approved in China and the United States. We created a database of approved ICIs by extracting the information of interest from the drug labels and reviewing documents disclosed on the official websites of the US Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) and compared the difference between the marketed ICIs in China and the United States regarding the number of indications, tumor types, review time, treatment setting, and so forth. Until June 30, 2022, 9 and 15 ICIs had been approved for 86 and 58 indications in the United States and China, involving 20 and 14 types of tumors, respectively. The correlation between indications and disease incidence was higher in China (r = 0.64) than in the United States (r = 0.45). About half of the indications were approved as first-line therapies in combination with chemotherapy, target therapy, or immunotherapy. Over 30% of indications were approved under accelerated or conditional approval in the two countries. A shorter regulatory review time was required by the FDA (median:181 days) compared to the NMPA (median: 279 days) for the new indication approval. Five ICIs marketed in China were approved by the FDA before the NMPA, with the median launch delay for the same indication of 344 days in China. A differentiated clinical development program that focuses on meeting unmet needs may bring new success for subsequent ICI products.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
强壮的人完成签到,获得积分10
刚刚
lxx完成签到 ,获得积分10
1秒前
yifan92完成签到,获得积分10
2秒前
2秒前
TS完成签到,获得积分10
2秒前
忘的澜完成签到,获得积分10
3秒前
4秒前
陆晓亦完成签到,获得积分10
4秒前
飞鸿踏雪泥完成签到 ,获得积分10
5秒前
所所应助zai采纳,获得10
5秒前
wanci应助乐于助人大好人采纳,获得10
5秒前
tananna完成签到,获得积分10
5秒前
111完成签到,获得积分10
6秒前
6秒前
YY发布了新的文献求助10
7秒前
月牙弯弯发布了新的文献求助10
7秒前
Vce April完成签到,获得积分10
7秒前
绿绿完成签到,获得积分10
7秒前
科研通AI2S应助baolong采纳,获得10
8秒前
8秒前
9秒前
大蓝蓝放电水母完成签到,获得积分10
11秒前
坚定的海露完成签到,获得积分10
11秒前
火星上的盼秋完成签到,获得积分10
11秒前
泥過完成签到 ,获得积分10
11秒前
果不欺然发布了新的文献求助10
12秒前
12秒前
13秒前
灵巧的yu完成签到,获得积分10
13秒前
xie完成签到,获得积分10
14秒前
14秒前
上官若男应助baozi采纳,获得10
15秒前
广州南完成签到 ,获得积分10
16秒前
16秒前
陌子完成签到 ,获得积分10
19秒前
zai发布了新的文献求助10
20秒前
聂难敌发布了新的文献求助10
20秒前
沙世平完成签到,获得积分10
21秒前
互助遵法尚德完成签到,获得积分0
21秒前
abbsdan发布了新的文献求助150
21秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162599
求助须知:如何正确求助?哪些是违规求助? 2813541
关于积分的说明 7900687
捐赠科研通 2473052
什么是DOI,文献DOI怎么找? 1316652
科研通“疑难数据库(出版商)”最低求助积分说明 631452
版权声明 602175